[144] Ascendis Pharma A/S American SEC Filing
Ascendis Pharma A/S (ASND) filing a Form 144 notifies the market of a proposed sale of 3,000 American Depositary Shares with an aggregate market value of $578,385. The shares represent part of 55,635,376 shares outstanding and are scheduled for sale on 08/20/2025 through Goldman Sachs & Co. LLC. The filer reports acquisition of the 3,000 ADS on 08/20/2025 via warrant exercise and payment in cash. The filing states there were no sales by the filer in the prior three months and includes the standard Rule 144 representation about no undisclosed material adverse information.
Ascendis Pharma A/S (ASND) ha presentato un Form 144 per notificare il mercato della proposta vendita di 3.000 American Depositary Shares per un valore complessivo di $578.385. Le azioni fanno parte di un totale di 55.635.376 azioni in circolazione e la vendita 猫 prevista per il 20/08/2025 tramite Goldman Sachs & Co. LLC. Il dichiarante segnala di aver acquisito le 3.000 ADS il 20/08/2025 mediante esercizio di warrant e pagamento in contanti. Nel documento si precisa che non ci sono state cessioni da parte del dichiarante nei tre mesi precedenti e include la consueta dichiarazione ai sensi della Rule 144 circa l'assenza di informazioni materiali non divulgate.
Ascendis Pharma A/S (ASND) present贸 un Form 144 para notificar al mercado una propuesta de venta de 3.000 American Depositary Shares por un valor agregado de $578,385. Las acciones pertenecen a un total de 55.635.376 acciones en circulaci贸n y la venta est谩 programada para el 20/08/2025 a trav茅s de Goldman Sachs & Co. LLC. El declarante informa que adquiri贸 las 3.000 ADS el 20/08/2025 mediante el ejercicio de warrants y pago en efectivo. La presentaci贸n indica que no hubo ventas por parte del declarante en los tres meses anteriores e incluye la representaci贸n est谩ndar de la Rule 144 sobre la ausencia de informaci贸n material no divulgada.
Ascendis Pharma A/S (ASND)臧� Form 144毳� 鞝滌稖頃� 鞁滌灔鞐� 3,000 American Depositary Shares毳� 齑濎暋 $578,385鞐� 毵る弰頃� 鞓堨爼鞛勳潉 韱奠頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 齑� 氚滍枆欤检嫕靾� 55,635,376欤检潣 鞚茧秬鞚措┌, 毵る弰 鞓堨爼鞚检潃 2025-08-20搿� Goldman Sachs & Co. LLC毳� 韱淀暣 歆勴枆霅╇媹雼�. 鞝滌稖鞛愲姅 3,000 ADS毳� 2025-08-20鞐� 鞗岆煱韸� 頄夓偓鞕� 順勱笀 歆�旮夓溂搿� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 靹滊鞐愲姅 鞝滌稖鞛愱皜 斓滉芳 3臧滌洈臧� 毵る弰頃� 氚� 鞐嗢潓鞚� 氇呾嫓頃橁碃 鞛堨溂氅�, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵�鞝曥爜 鞝曤炒臧� 鞐嗠嫟電� Rule 144鞚� 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Ascendis Pharma A/S (ASND) a d茅pos茅 un Form 144 pour informer le march茅 d'une proposition de vente de 3 000 American Depositary Shares pour une valeur totale de 578 385 $. Ces actions font partie des 55 635 376 actions en circulation et la vente est pr茅vue le 20/08/2025 via Goldman Sachs & Co. LLC. Le d茅clarant indique avoir acquis les 3 000 ADS le 20/08/2025 par l'exercice de warrants et paiement en esp猫ces. Le dossier pr茅cise qu'il n'y a eu aucune vente par le d茅clarant au cours des trois mois pr茅c茅dents et inclut la repr茅sentation standard de la Rule 144 concernant l'absence d'informations d茅favorables mat茅rielles non divulgu茅es.
Ascendis Pharma A/S (ASND) hat ein Form 144 eingereicht, um den Markt 眉产别谤 den geplanten Verkauf von 3.000 American Depositary Shares mit einem Gesamtwert von $578.385 zu informieren. Die Aktien sind Teil der insgesamt 55.635.376 ausstehenden Aktien; der Verkauf ist f眉r den 20.08.2025 眉产别谤 Goldman Sachs & Co. LLC vorgesehen. Der Melder gibt an, die 3.000 ADS am 20.08.2025 durch Aus眉bung von Warrants und Barzahlung erworben zu haben. In der Einreichung hei脽t es, dass der Melder in den vorangegangenen drei Monaten keine Verk盲ufe get盲tigt hat und es ist die 眉bliche Rule-144-Erkl盲rung enthalten, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
- None.
- None.
Insights
TL;DR: Routine Rule 144 notice for a small proposed sale following a warrant exercise; appears to be a compliance disclosure, not material company news.
The filing discloses a proposed sale of 3,000 ADS valued at $578,385 to be executed through Goldman Sachs on 08/20/2025. The securities were acquired the same day via warrant exercise and paid in cash, and no sales occurred in the prior three months. For investors, this is a transactional disclosure required under Rule 144 and does not itself provide information on company operations or financial performance. The size of the sale relative to outstanding shares (3,000 versus 55,635,376) suggests limited market impact absent larger, related insider activity.
TL;DR: Filing reflects appropriate insider disclosure and the standard Rule 144 attestation; governance processes appear followed.
The notice identifies the broker, acquisition method (warrant exercise), payment method (cash), and affirms the filer is not aware of undisclosed material adverse information. These elements are consistent with compliance expectations for insider sales under Rule 144. The absence of reported sales in the prior three months and the explicit representation reduce procedural concerns, though the filing does not include identity details of the selling person or relationship to the issuer in the provided text.
Ascendis Pharma A/S (ASND) ha presentato un Form 144 per notificare il mercato della proposta vendita di 3.000 American Depositary Shares per un valore complessivo di $578.385. Le azioni fanno parte di un totale di 55.635.376 azioni in circolazione e la vendita 猫 prevista per il 20/08/2025 tramite Goldman Sachs & Co. LLC. Il dichiarante segnala di aver acquisito le 3.000 ADS il 20/08/2025 mediante esercizio di warrant e pagamento in contanti. Nel documento si precisa che non ci sono state cessioni da parte del dichiarante nei tre mesi precedenti e include la consueta dichiarazione ai sensi della Rule 144 circa l'assenza di informazioni materiali non divulgate.
Ascendis Pharma A/S (ASND) present贸 un Form 144 para notificar al mercado una propuesta de venta de 3.000 American Depositary Shares por un valor agregado de $578,385. Las acciones pertenecen a un total de 55.635.376 acciones en circulaci贸n y la venta est谩 programada para el 20/08/2025 a trav茅s de Goldman Sachs & Co. LLC. El declarante informa que adquiri贸 las 3.000 ADS el 20/08/2025 mediante el ejercicio de warrants y pago en efectivo. La presentaci贸n indica que no hubo ventas por parte del declarante en los tres meses anteriores e incluye la representaci贸n est谩ndar de la Rule 144 sobre la ausencia de informaci贸n material no divulgada.
Ascendis Pharma A/S (ASND)臧� Form 144毳� 鞝滌稖頃� 鞁滌灔鞐� 3,000 American Depositary Shares毳� 齑濎暋 $578,385鞐� 毵る弰頃� 鞓堨爼鞛勳潉 韱奠頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 齑� 氚滍枆欤检嫕靾� 55,635,376欤检潣 鞚茧秬鞚措┌, 毵る弰 鞓堨爼鞚检潃 2025-08-20搿� Goldman Sachs & Co. LLC毳� 韱淀暣 歆勴枆霅╇媹雼�. 鞝滌稖鞛愲姅 3,000 ADS毳� 2025-08-20鞐� 鞗岆煱韸� 頄夓偓鞕� 順勱笀 歆�旮夓溂搿� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 靹滊鞐愲姅 鞝滌稖鞛愱皜 斓滉芳 3臧滌洈臧� 毵る弰頃� 氚� 鞐嗢潓鞚� 氇呾嫓頃橁碃 鞛堨溂氅�, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵�鞝曥爜 鞝曤炒臧� 鞐嗠嫟電� Rule 144鞚� 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Ascendis Pharma A/S (ASND) a d茅pos茅 un Form 144 pour informer le march茅 d'une proposition de vente de 3 000 American Depositary Shares pour une valeur totale de 578 385 $. Ces actions font partie des 55 635 376 actions en circulation et la vente est pr茅vue le 20/08/2025 via Goldman Sachs & Co. LLC. Le d茅clarant indique avoir acquis les 3 000 ADS le 20/08/2025 par l'exercice de warrants et paiement en esp猫ces. Le dossier pr茅cise qu'il n'y a eu aucune vente par le d茅clarant au cours des trois mois pr茅c茅dents et inclut la repr茅sentation standard de la Rule 144 concernant l'absence d'informations d茅favorables mat茅rielles non divulgu茅es.
Ascendis Pharma A/S (ASND) hat ein Form 144 eingereicht, um den Markt 眉产别谤 den geplanten Verkauf von 3.000 American Depositary Shares mit einem Gesamtwert von $578.385 zu informieren. Die Aktien sind Teil der insgesamt 55.635.376 ausstehenden Aktien; der Verkauf ist f眉r den 20.08.2025 眉产别谤 Goldman Sachs & Co. LLC vorgesehen. Der Melder gibt an, die 3.000 ADS am 20.08.2025 durch Aus眉bung von Warrants und Barzahlung erworben zu haben. In der Einreichung hei脽t es, dass der Melder in den vorangegangenen drei Monaten keine Verk盲ufe get盲tigt hat und es ist die 眉bliche Rule-144-Erkl盲rung enthalten, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
